Results 81 to 90 of about 1,950 (155)
Italian Journal of MedicinePremises and Purpose of the Study: Inflammation may contribute to erythropoiesis-stimulating agent (ESA) hyporesponsiveness. This pooled analysis evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase ...
doaj +1 more source
Safety of Roxadustat in Chronic Kidney Disease Patients: An Updated Systematic Review and Meta-Analysis. [PDF]
Pharmaceuticals (Basel)Background/Objectives: Roxadustat is a new treatment for the anemia of chronic kidney disease (CKD) that has comparable efficacy to erythropoietic-stimulating agents (ESAs), with the advantage of oral administration and increased iron bioavailability. It
Martínez-Miguel P +4 more
europepmc +2 more sources
Italian Journal of MedicinePremises and Purpose of the Study: Inflammation may cause erythropoiesis-stimulating agent (ESA) hyporesponsiveness for patients with anemia of chronic kidney disease (CKD).
doaj +1 more source
Effect of roxadustat on lowering blood lipids in peritoneal dialysis patients with anemia
Renal FailureObjectives To observe the effect of roxadustat on lowering blood lipids in peritoneal dialysis (PD) patients beyond treating anemia.Methods In a prospective, multicenter clinical study, we randomly assigned (in a 1:1 ratio) 100 PD patients who had ...
Tian Xu +13 more
doaj +1 more source
Effect of Roxadustat on Microinflammatory Status in Patients with Chronic Kidney Disease
Background. Roxadustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), has demonstrated multifaceted benefits in treating anemia of chronic kidney disease (CKD), yet the precise mechanism underlying its anti-inflammatory ...
Ying Xu +6 more
core +1 more source
Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients
, 2016 Safety concerns with erythropoietin analogues and intravenous (IV) iron for treatment of anemia in CKD necessitate development of safer therapies. Roxadustat (FG-4592) is an orally bioavailable hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor ...
Kumbar, Lalathaksha +14 more
core +2 more sources
BMC NephrologyObjective This study aims to investigate the impact of hypoxia-inducing factor prolyl hydroxylase inhibitor (HIF-PHI), specifically Roxadustat, on blood pressure variability, blood pressure indices, hemoglobin, and other biochemical markers in ...
Yu-ting Yang +10 more
doaj +1 more source
Background Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), exerts pleiotropic effects beyond erythropoiesis, including modulation of inflammation and immune responses.
Yang Zhao, Wen Tang, Ya-Hui Yang
core +1 more source
Roxadustat y daprodustat para el manejo de la anemia en la enfermedad renal crónica
, 2023 Introduction: Roxadustat and daprodustat, inhibitors of hypoxia-inducible factor prolyl hydroxylase, are a new class of oral drugs used for the treatment of anemia in chronic kidney disease.
Mejía Campoverde, Lauro Hernán +1 more
core